

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	Lockyer	CONF. NO.:	1674
SERIAL NO.:	10/560,956	GROUP NO.:	Not yet assigned
FILING DATE:	December 15, 2005	EXAMINER:	Not yet assigned
TITLE:	METHODS FOR IDENTIFYING COMPOUNDS INTERACTING WITH SMALL MEMBRANE-BOUND GTP-ASES		

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. 1.98(a)(2), only copies of the foreign patent documents and non-patent publications are enclosed.

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and

- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

#### **STATEMENT**

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Information Disclosure Statement  
U.S. Serial No.: 10/560,956  
Atty. Docket No.: MKC-008

Respectfully submitted,

Date: July 19, 2006  
Reg. No. 58,312

Tel. No.: (617) 570-1657  
Fax No.: (617) 523-1231

VER 9/00  
LIBC/2798334.1

A handwritten signature in black ink, appearing to read "Randall D. Morin", is positioned above a horizontal line.

Randall D. Morin  
Attorney for Applicants  
Goodwin Procter LLP  
Exchange Place  
Boston, Massachusetts 02109  
Goodwin Customer No. 051414

<b>FORM PTO - 1449</b>				<b>ATTORNEY DOCKET NO.: MKC-008</b>					
<b>INFORMATION DISCLOSURE STATEMENT</b>				<b>APPLICANT(S): Lockyer</b>					
				<b>SERIAL NO.: 10/560,956</b>					
				<b>FILING DATE: December 15, 2005</b>					
<b>U.S. PATENT DOCUMENTS</b>									
<b>EXAM. INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE IF APPROPRIATE</b>		
<b>FOREIGN PATENT DOCUMENTS</b>									
<b>EXAM. INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY CODE</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE</b>	<b>ABSTRACT ONLY</b>	<b>ENG LANG (Y/N)</b>
	B1	WO 98/37196	08/27/1998	PCT					Y
	B2	WO 02/008245	01/31/2002	PCT					Y
	B3	WO 02/052272	07/04/2002	PCT					Y
<b>OTHER ART, JOURNAL ARTICLES, ETC.</b>									
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>								
	C1	Barbacid, M., "ras GENES" (1987) <u>Ann. Rev. Biochem.</u> 56: 779-827.							
	C2	Bos, J., "ras Oncogenes in Human Cancer: A Review" (1989) <u>Cancer Research</u> 49(17): 4682-4689.							
	C3	Campbell, S., <i>et al.</i> , "Increasing complexity of Ras signaling" (1988) <u>Oncogene</u> 17(11): 1395-1413.							
	C4	Chiu, V. <i>et al.</i> , "Ras signalling on the endoplasmic reticulum and the Golgi" (2002) <u>Nature Cell Biology</u> 4: 343-350.							
	C5	Cichowski, K. <i>et al.</i> , "NF1 Tumor Suppressor Gene Function: Narrowing the GAP" (2001) <u>Cell</u> 104(4): 593-604.							
	C6	Cullen, P. <i>et al.</i> , "Integration of Calcium and Ras Signaling" (2002) <u>Nature Reviews Molecular Cell Biology</u> 3(5): 339-348.							
	C7	Dorn, G. <i>et al.</i> , "Intracellular Transport Mechanisms of Signal Transducers" (2002) <u>Annu. Rev. Physiol.</u> 64:407-29.							
	C8	Dorn, G. <i>et al.</i> , "Sustained <i>in vivo</i> cardiac protection by a rationally designed peptide that causes $\epsilon$ protein kinase C translocation" (1999) <u>Proc. Natl. Acad. Sci. USA</u> 96(22): 12798-12803.							
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>				

FORM PTO - 1449		ATTORNEY DOCKET NO.: MKC-008
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Lockyer
		SERIAL NO.: 10/560,956
		FILING DATE: December 15, 2005
OTHER ART, JOURNAL ARTICLES, ETC.		
EXA M. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C9	Gibbs, J. <i>et al.</i> , "Modulation of Guanine Nucleotides Bound to Ras in NIH3T3 Cells by Oncogenes, Growth Factors, and the GTPase Activating Protein (GAP)" (1990) <u>Jrl. of Biol. Chem.</u> 265(33): 20437-20442.
	C10	Ho, M. <i>et al.</i> , "Amplification of Wild-Type K-ras Promotes Growth of Head and Neck Squamous Cell Carcinoma" (2002) <u>Cancer Research</u> 62(24): 7154-7156.
	C11	Kato-Stankiewicz, J. <i>et al.</i> , "Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells" (2002) <u>Proc. Natl. Acad. Sci. USA</u> 99:14398-14403.
	C12	Kim, S.H. <i>et al.</i> , "E-cadherin -mediated Cell-Cell Attachment Activates Cdc42" (2000) <u>Jrl. of Biol. Chem.</u> 275: 36999-37005.
	C13	Lockyer, P. <i>et al.</i> , "CAPRI regulates Ca <sup>2+</sup> -dependent inactivation of the Ras-MAPK pathway" (2001) <u>Current Biology</u> 11(12): 981-986.
	C14	Nori M. <i>et al.</i> , "Inhibition of v-src-Induced Transformation by a GTPase-Activating Protein" (1991) <u>Molecular and Cellular Biology</u> 11(5): 2812-2818.
	C15	Rodriguez, M. <i>et al.</i> , "RACK1, a Protein Kinase C Anchoring Protein, Coordinates the Binding of Activated Protein Kinase C and Select Pleckstrin Homology Domains in Vitro" (1999) <u>Biochemistry</u> 38(42): 13787-13794.
	C16	Ron, D. <i>et al.</i> , "An autoregulatory region in protein kinase C: The pseudoanchoring site" (1995) <u>Proc. Natl. Acad. Sci. USA</u> 92(2): 492-496.
	C17	Ron, D. <i>et al.</i> , "Cloning of an intracellular receptor for protein kinase C: A homolog of the $\beta$ subunit of G proteins" (1994) <u>Proc. Natl. Acad. Sci. USA</u> 91(3): 839-843.
	C18	Ron, D. <i>et al.</i> , "C2 Region-derived Peptides Inhibit Translocation and Function of $\beta$ Protein Kinase C <i>in Vivo</i> " (1995) <u>Jrl. of Biol. Chem.</u> 270(41): 24180-24187.
	C19	Smith, M. <i>et al.</i> , "Requirement for c-ras proteins during viral oncogene transformation" (1986) <u>Nature</u> 320(6062): 540-543.
	C20	Srinivasan, S., "Rac and Cdc42 play distinct roles in regulating PI(3,4,5)P <sub>3</sub> and polarity during neutrophil chemotaxis" (2003) <u>Jrl. of Cell Biology</u> 160: 375-385.
	C21	International Search Report for International Application No. PCT/GB2004/001765, completed September 10, 2004, 1 page.
	C22	Great Britain Search Report under Section 17 for Application No.: GB 0314980.4, completed October 13, 2003, 1 page.
EXAMINER		DATE CONSIDERED